• 1
    Rossner S. Obesity: the disease of the twenty-first century. Int J Obes Relat Metab Disord 2002; 26 (Suppl. 4): S24.
  • 2
    Argiles JM, Azcon-Bieto J. The metabolic environment of cancer. Mol Cell Biochem 1988; 81: 317.
  • 3
    Argiles JM, Lopez-Soriano J, Busquets S et al. Journey from cachexia to obesity by TNF. FASEB J 1997; 11: 74351.
  • 4
    Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 37789.
  • 5
    Sharma AM. Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 2002; 26 (Suppl. 4): S57.
  • 6
    Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 182130.
  • 7
    Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796808.
  • 8
    Qi C, Pekala PH. Tumor necrosis factor-alpha-induced insulin resistance in adipocytes. Proc Soc Exp Biol Med 2000; 223: 12835.
  • 9
    Hausman DB, DiGirolamo M, Bartness TJ et al. The biology of white adipocyte proliferation. Obes Rev 2001; 2: 23954.
  • 10
    Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72: 366670.
  • 11
    Beutler B, Greenwald D, Hulmes JD et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316: 5524.
  • 12
    Scuderi P, Sterling KE, Lam KS et al. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1986; 2: 13645.
  • 13
    Waage A, Espevik T, Lamvik J. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients. Scand J Immunol 1986; 24: 73943.
  • 14
    Karayiannakis AJ, Syrigos KN, Polychronidis A et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 2001; 21: 13558.
  • 15
    Balkwill F, Osborne R, Burke F et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987; 2: 122932.
  • 16
    Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2: 86271.
  • 17
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 8791.
  • 18
    Uysal KT, Wiesbrock SM, Marino MW et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 6104.
  • 19
    Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 240915.
  • 20
    Xu H, Uysal KT, Becherer JD et al. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes 2002; 51: 187683.
  • 21
    Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196200.
  • 22
    Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 4565.
  • 23
    Orlinick JR, Chao MV. TNF-related ligands and their receptors. Cell Signal 1998; 10: 54351.
  • 24
    Liu ZG, Han J. Cellular responses to tumor necrosis factor. Curr Issues Mol Biol 2001; 3: 7990.
  • 25
    Tartaglia LA, Ayres TM, Wong GH et al. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 84553.
  • 26
    Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 16345.
  • 27
    Kelliher MA, Grimm S, Ishida Y et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297303.
  • 28
    Hsu H, Shu HB, Pan MG et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84: 299308.
  • 29
    Malinin NL, Boldin MP, Kovalenko AV et al. MAP3 K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997; 385: 5404.
  • 30
    Natoli G, Costanzo A, Moretti F et al. Tumor necrosis factor (TNF) receptor 1 signaling downstream of TNF receptor-associated factor 2. Nuclear factor kappaB (NFkappaB)-inducing kinase requirement for activation of activating protein 1 and NFkappaB but not of c-Jun N-terminal kinase/stress-activated protein kinase. J Biol Chem 1997; 272: 2607982.
  • 31
    Natoli G, Costanzo A, Ianni A et al. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 1997; 275: 2003.
  • 32
    Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol 1999; 71: 479500.
  • 33
    Chiariello M, Gutkind JS. Regulation of mitogen-activated protein kinases by G-protein-coupled receptors. Methods Enzymol 2002; 345: 43747.
  • 34
    Van Den Blink B, Ten Hove T, Van Den Brink GR et al. From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn’s disease. Ann N Y Acad Sci 2002; 973: 34958.
  • 35
    Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272: 9716.
  • 36
    Hotamisligil GS, Murray DL, Choy LN et al. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994; 91: 48548.
  • 37
    Hotamisligil GS, Budavari A, Murray D et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94: 15439.
  • 38
    Peraldi P, Hotamisligil GS, Buurman WA et al. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 1996; 271: 1301822.
  • 39
    Hotamisligil GS, Peraldi P, Budavari A et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 6658.
  • 40
    Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 1997; 100: 18639.
  • 41
    Lofgren P, Van Harmelen V, Reynisdottir S et al. Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes 2000; 49: 68892.
  • 42
    Green A, Dobias SB, Walters DJ et al. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology 1994; 134: 25818.
  • 43
    Ryden M, Dicker A, Van Harmelen V et al. Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem 2002; 277: 108591.
  • 44
    Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002; 18 (Suppl. 2): S59.
  • 45
    Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003; 14: 44755.
  • 46
    Gasic S, Tian B, Green A. Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations. J Biol Chem 1999; 274: 67705.
  • 47
    Zhang HH, Halbleib M, Ahmad F et al. Tumor necrosis factor-{alpha} stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 2002; 51: 292935.
  • 48
    Rydén M, Arvidsson E, Blomqvist L et al. Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 2004; 318(1): 16875.
  • 49
    Souza SC, De Vargas LM, Yamamoto MT et al. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor alpha to increase lipolysis in 3T3-L1 adipocytes. J Biol Chem 1998; 273: 246659.
  • 50
    Tansey JT, Sztalryd C, Gruia-Gray J et al. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci U S A 2001; 98: 64949.
  • 51
    Martinez-Botas J, Anderson JB, Tessier D et al. Absence of perilipin results in leanness and reverses obesity in Lepr(db/db) mice. Nat Genet 2000; 26: 4749.
  • 52
    Londos C, Brasaemle DL, Schultz CJ et al. Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin Cell Dev Biol 1999; 10: 518.
  • 53
    Moore HP, Silver RB, Mottillo EP et al. Perilipin targets a novel pool of lipid droplets for lipolytic attack by hormone-sensitive lipase. J Biol Chem 2005; 280: 4310920.
  • 54
    Miyoshi H, Souza SC, Zhang HH et al. Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation-dependent and -independent mechanisms. J Biol Chem 2006; 281: 1583744.
  • 55
    Granneman JG, Moore HP, Granneman RL et al. Analysis of lipolytic protein trafficking and interactions in adipocytes. J Biol Chem 2007; 282(8): 572635.
  • 56
    Marcinkiewicz A, Gauthier D, Garcia A et al. The phosphorylation of serine 492 of perilipin a directs lipid droplet fragmentation and dispersion. J Biol Chem 2006; 281: 119019.
  • 57
    Dahlman I, Linder K, Arvidsson Nordstrom E et al. Changes in adipose tissue gene expression with energy-restricted diets in obese women. Am J Clin Nutr 2005; 81: 127585.
  • 58
    Nordstrom EA, Ryden M, Backlund EC et al. A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-alpha)-like effector A (CIDEA) in adipocyte lipolysis and obesity. Diabetes 2005; 54: 172634.
  • 59
    Dahlman I, Forsgren M, Sjogren A et al. Downregulation of electron transport chain genes in visceral adipose tissue in type 2 diabetes independent of obesity and possibly involving tumor necrosis factor-{alpha}. Diabetes 2006; 55: 17929.
  • 60
    Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 41152.
  • 61
    Wallach D, Varfolomeev EE, Malinin NL et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17: 33167.
  • 62
    Grutter MG. Caspases: key players in programmed cell death. Curr Opin Struct Biol 2000; 10: 64955.
  • 63
    Gupta S. A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol 2002; 22: 18594.
  • 64
    Roulston A, Reinhard C, Amiri P et al. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 1998; 273: 102329.
  • 65
    Cardone MH, Salvesen GS, Widmann C et al. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 1997; 90: 31523.
  • 66
    Ichijo H, Nishida E, Irie K et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997; 275: 904.
  • 67
    Huang S, Jiang Y, Li Z et al. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 1997; 6: 73949.
  • 68
    Zanke BW, Boudreau K, Rubie E et al. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr Biol 1996; 6: 60613.
  • 69
    Goillot E, Raingeaud J, Ranger A et al. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci U S A 1997; 94: 33027.
  • 70
    Zhang X, Shan P, Otterbein LE et al. Carbon monoxide inhibition of apoptosis during ischemia-reperfusion lung injury is dependent on the p38 mitogen-activated protein kinase pathway and involves caspase 3. J Biol Chem 2003; 278: 124858.
  • 71
    Prins JB, Niesler CU, Winterford CM et al. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes 1997; 46: 193944.
  • 72
    Arner P. Regional differences in protein production by human adipose tissue. Biochem Soc Trans 2001; 29(Pt 2): 725.
  • 73
    Paquot N, Castillo MJ, Lefebvre PJ et al. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 13169.
  • 74
    Ofei F, Hurel S, Newkirk J et al. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDD. Diabetes 1996; 45: 8815.
  • 75
    Di Rocco P, Manco M, Rosa G et al. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes Res 2004; 12: 7349.
  • 76
    Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 13745.
  • 77
    Neel JV. Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress”? Am J Hum Genet 1962; 14: 35362.
  • 78
    Cornelius P, Enerback S, Bjursell G et al. Regulation of lipoprotein lipase mRNA content in 3T3-L1 cells by tumour necrosis factor. Biochem J 1988; 249: 7659.